Triptolide suppresses melanoma cell growth in vitro and in vivo through the Src-ERK signaling pathway

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Melanoma is an aggressive skin cancer with increasing incidence and high mortality.
• Metastasis is a key factor in melanoma-related deaths.
• The Src-ERK signaling pathway is crucial for melanoma cell growth and metastasis.

Purpose of the Study:

• To investigate the therapeutic potential of triptolide in melanoma.
• To elucidate the underlying molecular mechanisms of triptolide's action in melanoma cells.
• To evaluate triptolide's effects on melanoma cell proliferation, cell cycle, apoptosis, migration, and invasion.

Main Methods:

• In vitro experiments assessed cell proliferation, cell cycle, apoptosis, migration, and invasion in melanoma cell lines (SK-MEL-5, SK-MEL-28).
• In vivo studies utilized nude mouse xenograft models to evaluate therapeutic efficacy.
• Western blot analysis was employed to investigate the involvement of the Src-ERK pathway.

Main Results:

• Triptolide significantly reduced proliferation, migration, and invasion in melanoma cells.
• Triptolide induced G0/G1 cell cycle arrest and promoted apoptosis.
• These effects were mediated through the inhibition of the Src-ERK signaling pathway.

Conclusions:

• Triptolide demonstrates potent anti-melanoma activity by inhibiting cell growth and metastasis.
• The Src-ERK pathway is a key target for triptolide's anti-melanoma effects.
• Triptolide holds potential as a novel therapeutic agent for advanced and metastatic melanoma.